Familial Chylomicronemia Syndrome Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics

Posted on
by

Familial Chylomicronemia Syndrome Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics
The Key Familial Chylomicronemia Syndrome Companies in the amrket include – Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others.

 

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Familial Chylomicronemia Syndrome Market Report:

https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

 

Some of the key facts of the Familial Chylomicronemia Syndrome Market Report:

  • The Familial Chylomicronemia Syndrome market size was valued approximately USD 15 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In May 2026, Ionis Pharmaceuticals lowered the price of Tryngolza, from USD 595,000 to USD 40,000 which is 93% reduction ahead of anticipated label expansion.

  • In January 2026, Ionis Pharmaceuticals announced TRYNGOLZA outperformed expectations as the first US FDA approved treatment for FCS, generating USD 105 million in preliminary US net product sales in 2025.

  • In September 2025, Ionis Pharmaceuticals announced that TRYNGOLZA has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed FCS. The approval is based on positive data from the Phase III Balance study, in which TRYNGOLZA 80 mg significantly reduced fasting triglycerides at 6 months, with effects sustained to 12 months, lowered acute pancreatitis events, and showed good safety and tolerability.

  • In January 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the U.S. FDA has accepted the New Drug Application (NDA) for investigational plozasiran to treat familial chylomicronemia syndrome (FCS), a rare and severe genetic disorder. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and currently does not plan to hold an advisory committee meeting. Arrowhead also plans to seek regulatory approval for plozasiran in additional regions in 2025.

  • In 2025, the US accounted for the highest diagnosed prevalent cases of FCS with more then 1,300 cases. These cases are anticipated to increase during the forecast period.

  • Approximately 70% of individuals diagnosed with FCS are male, with a median age of diagnosis around 9 years, highlighting its early onset and male predominance.

  • Japan recorded more diagnosed cases of FCS than UK.

  • In 2025, the diagnosed burden of FCS in the US was higher in the 0–17 years age group compared to individuals aged 18 years and above, indicating a greater concentration of cases in the pediatric and adolescent population.

  • Most patients (>90%) found managing fat intake to be difficult, and 53% experienced symptoms despite adherence to their diets.

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

  • The Familial Chylomicronemia Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics.

 

Familial Chylomicronemia Syndrome Overview

Familial Chylomicronemia Syndrome is a rare genetic disorder characterized by the body’s inability to properly break down fats, leading to extremely high levels of triglycerides in the blood. This condition results from a deficiency or dysfunction of lipoprotein lipase (LPL), an enzyme crucial for the metabolism of chylomicrons, which are lipoproteins that transport dietary fats in the blood.

 

To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome Market Forecast

 

Familial Chylomicronemia Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Familial Chylomicronemia Syndrome Epidemiology Segmentation:

The Familial Chylomicronemia Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of Familial Chylomicronemia Syndrome

  • Prevalent Cases of Familial Chylomicronemia Syndrome by severity

  • Gender-specific Prevalence of Familial Chylomicronemia Syndrome

  • Diagnosed Cases of Episodic and Chronic Familial Chylomicronemia Syndrome

 

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome epidemiology trends @ Familial Chylomicronemia Syndrome Epidemiology Forecast

 

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Familial Chylomicronemia Syndrome Therapies and Key Companies

  • Olezarsen (TRYNGOLZA): Ionis Pharmaceuticals and Swedish Orphan Biovitrum

  • Volanesorsen (WAYLIVRA): Ionis Pharmaceuticals

  • ARO-APOC3: Arrowhead Pharma

  • VSA001 injection: Visirna Therapeutics HK Limited

  • Olezarsen: Ionis Pharmac

  • LCQ908: Novartis

  • AKCEA-ANGPTL3-LRx: Akcea Therapeutics

  • Volanesorsen: Akcea Therapeutics

  • Plozasiran: Arrowhead Pharmaceuticals

 

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome market share @ Familial Chylomicronemia Syndrome Treatment Market

 

Familial Chylomicronemia Syndrome Market Drivers

  • Rising awareness and improved diagnosis of rare genetic lipid disorders are increasing the identification of Familial Chylomicronemia Syndrome (FCS) patients worldwide.

  • Growing prevalence of severe hypertriglyceridemia and recurrent pancreatitis is driving demand for effective targeted therapies.

  • Advancements in genetic testing and precision medicine are supporting early detection and personalized treatment approaches for FCS patients.

  • Increasing research and development activities focused on ApoC-III inhibitors and RNA-based therapies are expanding the treatment landscape.

 

Familial Chylomicronemia Syndrome Market Barriers

  • The extremely rare nature of Familial Chylomicronemia Syndrome limits the patient pool and commercial market potential.

  • High treatment costs associated with advanced biologics and gene-targeted therapies may restrict patient accessibility.

  • Delayed or misdiagnosis due to lack of disease awareness among healthcare professionals remains a major challenge.

  • Strict dietary management requirements and poor patient adherence can impact treatment outcomes.

 

Scope of the Familial Chylomicronemia Syndrome Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

  • Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies

  • Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Familial Chylomicronemia Syndrome Unmet Needs, KOL’s views, Analyst’s views, Familial Chylomicronemia Syndrome Market Access and Reimbursement

 

To know more about Familial Chylomicronemia Syndrome companies working in the treatment market, visit @ Familial Chylomicronemia Syndrome Clinical Trials and Treatment

 

Table of Contents

1. Familial Chylomicronemia Syndrome Market Report Introduction

2. Executive Summary for Familial Chylomicronemia Syndrome

3. SWOT analysis of Familial Chylomicronemia Syndrome

4. Familial Chylomicronemia Syndrome Patient Share (%) Overview at a Glance

5. Familial Chylomicronemia Syndrome Market Overview at a Glance

6. Familial Chylomicronemia Syndrome Disease Background and Overview

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Chylomicronemia Syndrome

9. Familial Chylomicronemia Syndrome Current Treatment and Medical Practices

10. Familial Chylomicronemia Syndrome Unmet Needs

11. Familial Chylomicronemia Syndrome Emerging Therapies

12. Familial Chylomicronemia Syndrome Market Outlook

13. Country-Wise Familial Chylomicronemia Syndrome Market Analysis (2022–2036)

14. Familial Chylomicronemia Syndrome Market Access and Reimbursement of Therapies

15. Familial Chylomicronemia Syndrome Market Drivers

16. Familial Chylomicronemia Syndrome Market Barriers

17. Familial Chylomicronemia Syndrome Appendix

18. Familial Chylomicronemia Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/